SAN Sanofi

Press Release: Annual General Meeting of April 30, 2025

Press Release: Annual General Meeting of April 30, 2025

Annual General Meeting of April 30, 2025

  • Approval of the financial statements for the fiscal year 2024
  • Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025
  • Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress



Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders.

The General Meeting approved the individual Company and consolidated financial statements for the fiscal year 2024 and decided on the distribution of an ordinary annual dividend of €3.92 per share. The payment of the dividend will be made on May 14, 2025.

The General Meeting also renewed Carole Ferrand, Barbara Lavernos, Emile Voest and Antoine Yver as Directors, and ratified the cooptation of Jean-Paul Kress.

The Board of Directors is now composed of 16 Directors, including two directors representing employees. It has an independence rate of 78% and a gender diversity rate of 43%. It also has 8 directors of foreign nationality, i.e. a rate of 50 %.

On the proposal of the Appointments, Governance and CSR Committee, the Board of Directors has appointed Clotilde Delbos, independent Director, as Chairwoman of the Compensation Committee.

The voting results and the videocast of the Annual General Meeting are available .

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul | 25 |

Victor Rouault | 40 |

Nicolas Obrist | 55 |

Léo Le Bourhis | 81 |   

Léa Ubaldi | +33 (0)6 30 19 66 46 | 

Evan Berland | |   

Timothy Gilbert | 9 |

Investor Relations

Thomas Kudsk Larsen | 93 |

Alizé Kaisserian | 11 |

Felix Lauscher | 9 |

Keita Browne | 6 |

Nathalie Pham | 17 |

Tarik Elgoutni | 7 |

Thibaud Châtelet | 90 |  

Attachment



EN
30/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as t...

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placeboAFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring ...

 PRESS RELEASE

Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé au...

Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par une étude de phase 3 démontrant que Dupixent a réduit de manière significative les signes et symptômes nasaux ainsi que le recours aux corticostéroïdes systémiques ou à la chirurgie par rapport au placeboL’AFRS e...

 PRESS RELEASE

Press release: Filing of the 2025 U.S. Form 20-F and French “Document ...

Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s ...

 PRESS RELEASE

Communiqué de presse : Dépôt du Document d’Enregistrement Universel 20...

Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026. Sanofi annonce avoir déposé son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France et son « Form 20-F » auprès de la « Securities and Exchange Commission » (SEC) aux Etats-Unis. Le rapport du Conseil d’administration ...

 PRESS RELEASE

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data d...

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potent...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch